Concepedia

Immune Checkpoint Modulation

Immune Checkpoint Modulation is an immunopharmacotherapeutic strategy that selectively alters the activity of inhibitory or stimulatory immune checkpoint receptor–ligand pathways, typically via targeted biologics or small molecules, to enhance or restrain antigen-specific immune responses.

1.4K

Publications

126K

Citations

13.9K

Authors

2.5K

Institutions

Publications per year

2017–2026

1.2K

Parents

Children

Publications

1.4K

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

, , +17

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text

, , +17

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Douglas B. Johnson, Justin M. Balko, Margaret Compton et al. · New England Journal of Medicine · 2016 · 2.3K citations · Full text

, , +17

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Suzanne L. Topalian, Mario Sznol, David F. McDermott et al. · Journal of Clinical Oncology · 2014 · 2.2K citations

, , +17

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Kaori Sakuishi, Lionel Apétoh, Jenna M. Sullivan et al. · The Journal of Experimental Medicine · 2010 · 2.1K citations · Full text

, , +16

1–5 of 1.4K

Authors

13.9K

  1. FS
    F. Stephen Hodi

    Dana-Farber Cancer Institute, United States

    20 publications · 8.5K citations

    18

    h-index

  2. DS
    Dirk Schadendorf

    Heidelberg University, Germany

    17 publications · 3.9K citations

    14

    h-index

  3. CR
    Caroline Robert

    Institut Gustave Roussy, France

    13 publications · 4.4K citations

    13

    h-index

  4. PA
    Paolo A. Ascierto

    Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Italy

    13 publications · 2.7K citations

    13

    h-index

  5. JR
    Julie R. Brahmer

    Sidney Kimmel Comprehensive Cancer Center, United States

    14 publications · 14.4K citations

    13

    h-index

1–5 of 13.9K

Institutions

2.5K

  1. Dana-Farber Cancer Institute

    Boston, United States

    49 h-index

    331 publications

    81.8K citations

  2. The University of Texas MD Anderson Cancer Center

    Houston, United States

    45 h-index

    594 publications

    59.8K citations

  3. Harvard University

    Cambridge, United States

    44 h-index

    318 publications

    95K citations

  4. Memorial Sloan Kettering Cancer Center

    New York, United States

    39 h-index

    300 publications

    78.9K citations

  5. Massachusetts General Hospital

    Boston, United States

    38 h-index

    273 publications

    51.4K citations

  6. Brigham and Women's Hospital

    Boston, United States

    32 h-index

    90 publications

    37.9K citations

  7. Inserm

    Paris, France

    29 h-index

    292 publications

    32.3K citations

  8. Johns Hopkins University

    Baltimore, United States

    29 h-index

    302 publications

    94.1K citations

1–8 of 2.5K

Venues

  1. Journal for ImmunoTherapy of Cancer

    JITC · 72 publications · 4.5K citations

    41

    h-index

  2. Journal of Clinical Oncology

    110 publications · 10.2K citations

    38

    h-index

  3. Nature Communications

    30 publications · 5.7K citations

    28

    h-index

  4. OncoImmunology

    34 publications · 2.1K citations

    25

    h-index

  5. Cancer Immunology Research

    29 publications · 2.1K citations

    25

    h-index

1–5